← Back to Search

Other

ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome (EXCELLENCE Trial)

Phase 2 & 3
Waitlist Available
Research Sponsored by Anavex Life Sciences Corp.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks

Summary

This trial tests a liquid medicine called ANAVEX2-73 for children aged 5-17 with Rett Syndrome. The medicine is designed to improve brain function by targeting specific pathways. The study will last several weeks, with an option to continue for several months.

Eligible Conditions
  • Rett Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Incidents of Adverse Events
RSBQ
Secondary study objectives
Anxiety, Depression, and Mood Scale (ADAMS)
CGI-I
Child Health Questionnaire-Parent Form 50 (CHQ-PF50)
+6 more
Other study objectives
GABA Plasma Concentration
Genetic variant SIGMAR1, COMT
Glutamate Plasma Concentration
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: ANAVEX2-73 ActiveExperimental Treatment1 Intervention
ANAVEX2-73 liquid oral solution
Group II: ANAVEX2-73 PlaceboPlacebo Group1 Intervention
Placebo liquid oral solution
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ANAVEX2-73 oral liquid
2020
Completed Phase 3
~100

Find a Location

Who is running the clinical trial?

Anavex Life Sciences Corp.Lead Sponsor
12 Previous Clinical Trials
1,460 Total Patients Enrolled
2 Trials studying Rett Syndrome
64 Patients Enrolled for Rett Syndrome
Anavex Australia Pty Ltd.Industry Sponsor
4 Previous Clinical Trials
977 Total Patients Enrolled
Anavex Germany GmbHIndustry Sponsor
4 Previous Clinical Trials
1,073 Total Patients Enrolled
~17 spots leftby Dec 2025